ArticleBMC cancer2026
Electronic patient-reported outcome monitoring system for sarcoma patients undergoing drug treatment: a development and feasibility study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundSymptom and quality of life monitoring using electronic patient-reported outcomes has been widely adopted for common cancers. However, there are few such systems and studies for rare cancers such as sarcomas in Japan. We herein report a development and feasibility study of a novel system for monitoring electronic patient-reported outcomes.
methodsOur study group, which included clinical physicians and system engineers as a collaboration between academia and industry, developed the system and conducted weekly electronic patient-reported outcome monitoring for sarcoma patients during the administration of anti-tumor agents. This prospective study was conducted from 2021 to 2023, with each patient monitored for 12 weeks to 1 year.
resultsTwenty-three patients were included in this study. The weekly response rate and missing rate of the electronic patient-reported outcome system were 95.7% and 0.12%, respectively. The median time required to answer the items for Performance Status, EuroQol 5-Dimension 5-Level, and 14 symptoms from the Patient-Reported Outcome-Common Terminology Criteria for Adverse Events was 11 s, 46 s, and 123 s, respectively. In a comparison between electronic and paper-based patient-reported outcomes, the intraclass correlation coefficient of the EuroQol index score was 0.92 (95%CI: 0.89-0.94) and the weighted kappa coefficient was > 0.6 for items in the weekly evaluations. The items that showed the highest rate of moderate or severe grade (at least once in each case) in the whole cohort were general pain (82.6%), fatigue (78.3%), decreased appetite (73.9%) and pain/discomfort (73.9%).
conclusionsThe novel electronic patient-reported outcome monitoring system for Japanese sarcoma patients undergoing drug treatment is found to be feasible and showed excellent compliance. For the application of the system in clinical practice, an update to implement an alert function based on a precise predictive model, is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.